• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Opinion
Video

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

Video content above is prompted by the following questions:

  1. Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
    1. What was the objective of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=155
      2. Median follow-up: 21.78 months
      3. PFS
      4. ORR
      5. Median duration of response
      6. OS
      7. Safety
  2. Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
  3. Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?
Related Videos
Dr Ameet Patel
Peter Voorhees, MD, Atrium Health Levine Cancer Institute
Paula Rodríguez-Otero, MD, PhD
Peter Voorhees, MD, Atrium Health Levine Cancer Institute
Hearn Jay Cho, MD, PhD
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD
Kelley L. Julian, PharmD, BCOP
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD, Cancer Center Clínica Universidad de Navarra
Related Content
FDA approval | Image Credit: © Surendra-stock.adobe.com

FDA Green-Lights D-VRd Quadruplet for Newly Diagnosed Multiple Myeloma

January 27th 2026
Article

This approval brings the total indications for daratumumab and hyaluronidase to 5 in newly diagnosed disease and its 12th overall.

Read More

Roberto Mina, MD, Winship Cancer Institute of Emory University

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

January 23rd 2026
Article

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

Read More

Nashville | Image Credit: © f11photo-stock.adobe.com

Advancing Biomarker Testing Across GU, Lung, and Myeloma Care

January 22nd 2026
Article

Experts discuss the impact of biomarker testing on GU and lung cancers, as well as myeloma, emphasizing its role in personalized treatment and patient care advancements.

Read More

FDA | Image Credit: © Pakin-stock.adobe.com

FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval

January 21st 2026
Article

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Read More

Teclistamab | Image Credit: ©luchschenF-stock.adobe.com

MajesTEC-9 Data Add to Accolades for Teclistamab in Multiple Myeloma

January 15th 2026
Article

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Read More

CAR T-cell therapy

Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers

January 12th 2026
Article

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.